Core Viewpoint - Innovent Biologics has presented promising clinical data for IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, demonstrating breakthrough efficacy in treating "immune cold tumors" such as acral and mucosal melanoma, which are traditionally resistant to treatment [1][2][4]. Company Overview - Innovent Biologics is a leading biopharmaceutical company focused on developing high-quality medicines for various diseases, including oncology, cardiovascular, and autoimmune conditions [16]. - The company has launched 15 products and has multiple assets in various stages of clinical trials, indicating a robust pipeline [16]. Clinical Study Insights - IBI363 is currently undergoing clinical studies in China, the United States, and Australia, targeting multiple tumor indications, particularly immune-resistant and cold tumors [2][14]. - The Phase 1/2 studies have shown a confirmed objective response rate (cORR) of 23.3% and a disease control rate (DCR) of 76.7% in patients with advanced melanoma [6][7]. - The median progression-free survival (PFS) for patients treated with IBI363 was reported at 5.7 months, significantly longer than previous studies [7][10]. Efficacy and Safety Profile - IBI363 has demonstrated durable responses with a median duration of response (DoR) of 14.0 months in patients with confirmed responses [7]. - The overall 12-month overall survival (OS) rate was 61.5%, with a median OS of 14.8 months [6][7]. - The treatment was generally well tolerated, with the most common treatment-related adverse events being arthralgia, rash, and hyperthyroidism, primarily Grade 1 or 2 [7]. Future Development Plans - A pivotal Phase 2 registrational study comparing IBI363 with pembrolizumab in patients with unresectable melanoma has been initiated, aiming to enroll 180 patients [8][9]. - The company is also exploring combination therapies with IBI363 across various cancer types, indicating a commitment to expanding its therapeutic applications [9][14]. Market Need and Potential - There is a significant unmet clinical need for effective treatments for advanced acral and mucosal melanoma in China, where current therapies have limited efficacy [10][12]. - IBI363 aims to address this gap by transforming "cold tumors" into "hot tumors" through dual activation of the PD-1 and IL-2 pathways, potentially establishing a new standard in immunotherapy for melanoma [10][13].

Core Viewpoint - Innovent Biologics has initiated a Phase 3 clinical study for picankibart, targeting psoriasis patients who have not responded adequately to anti-IL-17 treatments, aiming to provide robust clinical evidence for biologic switching strategies in psoriasis treatment [1][4][6]. Company Overview - Innovent Biologics is a leading biopharmaceutical company founded in 2011, focused on developing high-quality medicines for various diseases, including oncologic, autoimmune, cardiovascular, and metabolic conditions [10]. - The company has launched 15 products and has multiple assets in various stages of clinical trials, including 3 new drug applications under regulatory review [10]. Clinical Study Details - The Phase 3 study (NCT06945107) will enroll approximately 310 participants, randomized in a 1:1 ratio to receive either picankibart or continued IL-17 monoclonal antibody treatment [2]. - The primary endpoint is the proportion of participants achieving a static Physician's Global Assessment (sPGA) score of clear (0) or almost clear (1) at week 16 [2]. Efficacy and Safety - Previous Phase 2 studies indicated that switching to picankibart resulted in a rapid clinical response, with 64.6% of patients achieving skin lesion clearance after 16 weeks [3][6]. - Nearly half (48.2%) of participants in the Phase 2 study reached the primary endpoint, with a stable response rate of 54.2% through week 44 [5]. Psoriasis Background - Psoriasis is a chronic inflammatory disease affecting 80%-90% of patients with plaque psoriasis, with nearly 30% classified as moderate-to-severe [7]. - Current systemic treatments include various agents, with biologics becoming a central focus since 2019 due to their efficacy and safety [7]. Picankibart Overview - Picankibart (IBI112) is a monoclonal antibody developed by Innovent, targeting the IL-23p19 subunit, which may offer a more effective treatment option for psoriasis and other autoimmune diseases [8]. - The first new drug application for picankibart for moderate-to-severe plaque psoriasis was submitted for review by the NMPA in September 2024 [9].

Summary of Innovent (1801.HK) Conference Call Company Overview - **Company**: Innovent Biologics, Inc. (1801.HK) - **Date**: 23 May 2025 - **Market Cap**: HK$92,786 million (approximately US$11,855 million) [2][9] Key Industry Insights - **Product Focus**: IBI363, an investigational drug for various cancers including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and melanoma. - **Clinical Data**: - In IO-treated squamous NSCLC, IBI363 demonstrated an overall response rate (ORR) of 43.3% (13/30) and a median progression-free survival (mPFS) of 7.3 months, suggesting potential superiority over docetaxel (mPFS ~4 months, mOS 10-12 months) [2][4]. - In third-line or later MSS/pMMR CRC, IBI363 showed an ORR of 23.5% (16/68) when combined with Bevacizumab (Beva) [2][4]. - **Regulatory Actions**: Innovent has initiated a registrational trial for IBI363 in IO-naïve melanoma and is in discussions with regulatory agencies regarding potential registrational trials in IO-treated squamous NSCLC and CRC [2][4]. Financial Projections - **Target Price**: HK$60.00, indicating an expected share price return of 6.7% [2][9]. - **Valuation Method**: Discounted Cash Flow (DCF) approach, with a terminal growth rate of 4% and a weighted average cost of capital (WACC) of 10.3% [9]. Risk Factors - **High Risk Rating**: The stock is classified as high risk due to: 1. Historical lack of profitability and forecasted periods without profit. 2. Potential sales underperformance relative to expectations. 3. Intense competition for IBI362 in obesity treatment. 4. Risks associated with research and development failures. 5. Regulatory risks that could hinder stock performance [10][2]. Additional Considerations - **Investment Rating**: The stock is rated as "Buy" with a high-risk designation, reflecting the volatility and fundamental criteria associated with the company [21][22]. - **Expected Dividend Yield**: 0.0%, indicating no dividends are anticipated in the near term [2][9]. This summary encapsulates the critical insights from the Innovent conference call, highlighting the company's clinical advancements, financial outlook, and associated risks.

Core Viewpoint - The article highlights the successful Phase III clinical trial results of the obesity treatment drug Masitide (GCG/GLP-1 dual receptor agonist), which has been published in the prestigious New England Journal of Medicine (NEJM), marking a significant milestone for China's innovation in the field of endocrine metabolism and potentially transforming obesity treatment globally [1][5][10]. Group 1: Clinical Research and Results - The GLORY-1 study, which included 610 participants, demonstrated that Masitide significantly reduced body weight compared to placebo, with 73.9% and 82.0% of participants in the 4 mg and 6 mg groups, respectively, achieving a weight loss of ≥5% by week 32 [9]. - By week 48, 35.7% and 49.5% of participants in the 4 mg and 6 mg groups, respectively, achieved a weight loss of ≥15%, while only 2.0% in the placebo group did [9]. - The drug also showed significant improvements in various metabolic indicators, including blood lipids, blood pressure, and liver fat content [9]. Group 2: Significance and Implications - The publication of the study in NEJM signifies international recognition of China's innovative drug development in the field of obesity treatment, providing a new direction for global obesity management [3][6]. - The research results are expected to influence clinical guidelines and practices, contributing to the "Healthy China 2030" initiative by addressing the rising obesity rates in the country [6][10]. - The dual-target mechanism of Masitide, which combines appetite suppression and enhanced fat metabolism, represents a breakthrough in obesity treatment strategies [8][10]. Group 3: Broader Context and Public Health - The increasing prevalence of overweight and obesity in China poses significant public health challenges, with obesity-related deaths accounting for 11.1% of chronic non-communicable disease deaths in 2019 [4]. - The Chinese government has initiated a "Weight Management Year" campaign to address these issues, emphasizing the importance of weight management in improving national health [4][6]. - Experts suggest that obesity treatment should consider local population characteristics and implement differentiated strategies, particularly focusing on liver health and lipid management [6][10].

Core Viewpoint - The company has presented preliminary data for IBI363 at the ASCO conference, demonstrating breakthrough efficacy in both hot tumors (NSCLC) and cold tumors (MSS CRC/mucosal melanoma) [1][2]. Group 1: Efficacy Data - In NSCLC, patients treated with IBI363 at a dose of 3 mg/kg showed a median progression-free survival (mPFS) of 7.3 months, indicating excellent performance [1][2]. - For MSS CRC, the median overall survival (mOS) reached 16.1 months in a mixed-dose single-agent treatment, approaching the benefits seen in first-line patients [1][3]. - In squamous NSCLC, the clinical objective response rate (cORR) was 36.7% with a disease control rate (DCR) of 90.0% [2]. - In cold tumors, IBI363 demonstrated an mOS of 16.1 months in MSS CRC, significantly exceeding the current treatment standard of 9-10 months [3][4]. Group 2: Safety Profile - The incidence of treatment-emergent adverse events (TEAEs) was reported at 99.3%, with 42.6% being grade 3 or higher [2]. - Only 6.6% of patients discontinued treatment due to TEAEs, and the mortality rate attributed to TEAEs was very low at 2.9% [2]. Group 3: Future Developments - The company plans to communicate with regulatory authorities regarding key registration clinical trials for squamous NSCLC, with expectations to initiate Phase III trials within the year [3][6]. - IBI363 is anticipated to reshape the immune environment for IO-resistant lung cancer patients, potentially replacing docetaxel as the new standard of care [2][4]. Group 4: Pipeline and Financial Outlook - The company is advancing its core pipeline, with expectations for multiple catalysts in 2025, including new indications for existing products [5][6]. - Revenue projections for the company are estimated at 11.856 billion, 15.613 billion, and 21.479 billion yuan for 2025-2027, with a target market valuation of 131.9 billion HKD [6].

Company Updates - On May 23, 2025 ASCO conference, several significant data were released by Innovent Biologics, including multiple oral presentations, notably the PoC data for IBI363 (PD-1/IL-2) in melanoma, colorectal cancer, and non-small cell lung cancer [1] - IBI363's colorectal cancer data exceeded expectations, with an overall objective response rate (ORR) of 12.7% for monotherapy and 23.5% for combination therapy, and a median overall survival (mOS) of 16.1 months for monotherapy [1] - In the context of IO-treated lung cancer, IBI363 demonstrated strong competitive advantages, with an ORR of 43.3% in the squamous NSCLC group at a 3 mg/kg dose [1] Key Data from ASCO - IBI363 showed an ORR of 26% and a median progression-free survival (mPFS) of 5.7 months in IO-treated mucosal/limb melanoma [2] - IBI343 (CLDN18.2 ADC) reported an ORR of 22.7%, mPFS of 5.4 months, and mOS of 8.5 months in CLDN18.2+ pancreatic ductal adenocarcinoma (PDAC), with 2L patients showing an mOS of 12.1 months [2] Profit Forecast and Valuation - The company maintains its net profit forecasts for 2025 and 2026 at 472 million and 1.298 billion respectively, and has raised the target price by 4.5% to HKD 69, indicating a potential upside of 22.7% from the current stock price [2]

Core Insights - The National Medical Products Administration (NMPA) has proposed to include Innovent Biologics' IBI363, a PD-1/IL-2 bispecific antibody fusion protein, in its breakthrough therapy designation for treating locally advanced or metastatic squamous non-small cell lung cancer that has failed platinum-based chemotherapy and anti-PD-1/PD-L1 immunotherapy [1][2] Group 1: Product Development - IBI363 is a globally innovative PD-1/IL-2α-bias bispecific fusion protein developed by Innovent Biologics, designed to block the PD-1/PD-L1 pathway while activating the IL-2 pathway [1] - The IL-2 arm of IBI363 has been engineered to retain affinity for IL-2 Rα while reducing binding to IL-2Rβ and IL-2Rγ, thereby lowering toxicity [1] - IBI363 has demonstrated good anti-tumor activity in various tumor-bearing pharmacology models and has shown significant tumor suppression efficacy in PD-1 resistant and metastatic models [1] Group 2: Clinical Research and Regulatory Status - IBI363 has previously been included in the breakthrough therapy drug (BTD) list by CDE, targeting unresectable locally advanced or metastatic acral and mucosal melanoma that has not undergone systemic treatment [2] - Innovent Biologics is conducting clinical studies in China, the United States, and Australia to explore the efficacy and safety of IBI363 against various malignancies [2] - IBI363 has received two Fast Track designations from the U.S. FDA for the treatment of advanced squamous non-small cell lung cancer and melanoma [2]

Core Viewpoint - The CSI Hong Kong Stock Connect Biotechnology Theme Index has shown significant growth, with a 5.26% increase over the past month, 20.82% over the past three months, and 25.29% year-to-date, reflecting strong performance in the biotechnology sector [1]. Group 1: Index Performance - The CSI Hong Kong Stock Connect Biotechnology Theme Index is currently at 1183.16 points, having been established with a base date of December 28, 2018, at 1000.0 points [1]. - The index comprises 50 listed companies involved in biopharmaceuticals, pharmaceuticals, and biotechnology services, selected from the Hong Kong Stock Connect range [1]. Group 2: Index Holdings - The top ten weighted companies in the index include: BeiGene (14.31%), WuXi Biologics (12.72%), Innovent Biologics (10.78%), CanSino Biologics (7.78%), CSPC Pharmaceutical Group (6.03%), China Biologic Products (5.8%), Hansoh Pharmaceutical (3.57%), Kelun-Biotech (3.31%), Zai Lab (3.29%), and WuXi AppTec (3.23%) [1]. - The index is fully composed of stocks listed on the Hong Kong Stock Exchange, with a 100% allocation [1]. Group 3: Industry Composition - The industry composition of the index holdings is as follows: biopharmaceuticals account for 50.37%, chemical drugs for 25.76%, pharmaceutical and biotechnology services for 20.60%, and medical devices for 3.27% [2]. - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December, with a sample adjustment limit of 20% [2].

Core Points - The CSI Hong Kong Stock Connect Innovative Drug Index decreased by 3.3% to 706.45 points, with a trading volume of 17.018 billion yuan on May 12 [1] - Over the past month, the index has increased by 16.02%, 20.90% over the last three months, and 25.61% year-to-date [1] - The index consists of 50 listed companies involved in innovative drug research and development, reflecting the overall performance of innovative drug companies within the Hong Kong Stock Connect [1] Index Composition - The top ten weighted companies in the index are: - Innovent Biologics (11.31%) - WuXi Biologics (10.96%) - BeiGene (9.29%) - CanSino Biologics (9.15%) - CSPC Pharmaceutical Group (7.19%) - China Biologic Products (6.94%) - Hansoh Pharmaceutical (4.18%) - WuXi AppTec (3.90%) - Zai Lab (3.88%) - 3SBio (3.45%) [1] - The index is exclusively composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation [1] Industry Breakdown - The industry composition of the index includes: - Biopharmaceuticals: 46.61% - Chemical drugs: 30.42% - Pharmaceutical and biotechnology services: 21.65% - Medical commerce and services: 1.32% [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2]

Investment Rating - The report maintains an "Outperform" rating for the company [2][9]. Core Insights - The company reported strong product revenue growth in Q1 2025, exceeding RMB 2.4 billion, which represents a year-on-year increase of 41% and a quarter-on-quarter increase of 13% [3][14]. - The commercial product portfolio has expanded to 15 products, with four new drugs launched in Q1 2025 [14][15]. - Upcoming approvals for innovative products are expected to drive further revenue growth throughout 2025 [3][19]. Financial Performance - Revenue projections for 2025, 2026, and 2027 are RMB 11.86 billion, RMB 14.34 billion, and RMB 18.09 billion, respectively, indicating year-on-year growth rates of 31%, 20%, and 26% [9][19]. - The company is expected to turn profitable in 2025, achieving a net profit of RMB 380 million [19][12]. - Gross profit margins are projected to remain strong, with estimates of 83.7% in 2025 and increasing to 88.0% by 2027 [12][19]. Product and R&D Developments - The company has launched four new drugs in Q1 2025, including IBI-344 (ROS1) and Limertinib (EGFR TKI) [14][15]. - The R&D pipeline is robust, with expectations for at least five new assets to enter global multi-regional clinical trials by 2030 [16][19]. - Key upcoming events include data updates for various clinical trials at major conferences, which are anticipated to enhance the company's market position [17][18]. Valuation - The target price for the company's stock has been revised to HKD 62.5 per share, based on a DCF model with a WACC of 9.8% and a terminal growth rate of 3.5% [9][19].